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Abstract
Background: Guidelines recommend an early initiation of aspirin treatment in patients with acute cerebral
ischemia. Comparative studies on the best starting dose for initiating aspirin therapy to achieve a rapid antiplatelet
effect do not exist. This study evaluated the platelet inhibitory effect in healthy volunteers by using three different
aspirin loading doses to gain a model for initiating antiplatelet treatment in acute strokes patients.
Methods: Using whole blood aggregometry, this study with a prospective, uncontrolled, open, crossover design
examined 12 healthy volunteers treated with three different aspirin loading doses: intravenous 500 mg aspirin, oral
500 mg aspirin, and a course of 200 mg aspirin on two subsequent days followed by a five-day course of 100 mg
aspirin. Aspirin low response was defined as change of impedance exceeding 0 Ω after stimulation with
arachidonic acid.
Results: Sufficient antiplatelet effectiveness was gained within 30 seconds when intravenous 500 mg aspirin was
used. The mean time until antiplatelet effect was 74 minutes for 500 mg aspirin taken orally and 662 minutes
(11.2 hours) for the dose scheme with 200 mg aspirin with a high inter- and intraindividual variability in those two
regimes. Platelet aggregation returned to the baseline range during the wash-out phase within 4 days.
Conclusion: Our study reveals that the antiplatelet effect differs significantly between the three different aspirin
starting dosages with a high inter- and intraindividual variability of antiplatelet response in our healthy volunteers.
To ensure an early platelet inhibitory effect in acute stroke patients, it could be advantageous to initiate the
therapy with an intravenous loading dose of 500 mg aspirin. However, clinical outcome studies must still define
the best way to initiate antiplatelet treatment with aspirin.
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Background
Initiating early antiplatelet therapy with aspirin (acetylsa-
licylic acid, ASA) is important in treating patients with
acute ischemic stroke or transient ischemic attacks
(TIAs) and has been proven to significantly decrease the
overall risk of further strokes or death [1-3]. Based on the
results of two large randomized trials with up to 40 000
patients, present guidelines recommend starting aspirin
treatment within 48 hours after stroke onset with doses
varying from 100 mg to 325 mg to reduce the risk of
early stroke recurrence [1-6].
Recommendations for the antiplatelet treatment of cor-
onary or peripheral disease cannot be transferred directly
to the treatment of patients with acute strokes. This fact
is ascribed to the heterogenic stroke causes and the
bleeding vulnerability of the brain after acute cerebrovas-
cular ischemia [7]. Treating acute stroke patients, neurol-
ogists commonly feel they are between Scylla and
Charybdis as they try to reduce the risk of recurrent
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excessive risk of cerebral bleeding when using antithrom-
b o t i ca g e n t s .D a t ao ft h eI S Ta n dC A S T - s t u d yg r o u p s
showed an insignificant increase of hemorrhagic stroke
or transformation with aspirin doses of either 160 mg or
300 mg and no elevated net hazard in patients who had
been inadvertently randomized after a hemorrhagic
stroke [1-3]. Still higher doses of aspirin could lead to an
increase of cerebral hemorrhage in analogy to dose-
dependent extracranial bleeding complications. Present-
day guideline recommendations on aspirin dosages for
acute stroke patients are based on these two major clini-
cal observational studies carried out in the Nineties. At
t h et i m et h e s es t u d i e sw e r em a d e ,t h e r ew a sn or o u t i n e
monitoring of the effectiveness of antiplatelet drugs.
As nowadays bedside testing of the antiplatelet effect
has become available using such tests as impedance
aggregometry, the antiplatelet effect of aspirin can be
monitored and calibrated much more easily in patients
with ischemic stroke. Given the limited data on how to
initiate aspirin treatment in stroke patients, our study
evaluated the dose-time response relationship of differ-
ent aspirin dosages in healthy volunteers. Using whole
blood aggregometry, the effect of three different aspirin
dosing regimens was assessed in order to find the best




12 healthy volunteers without any previous medical his-
tory or chronic drug therapy were enrolled in this study
after informed consent was obtained. The participants did
not have any history of bleeding diathesis, drug or alcohol
abuse, kidney or liver disease and abstained from any med-
ication two weeks prior to study initiation and during the
study protocol. In addition, normal prothrombin time, a
normal platelet count (within 150-400 × 10
9/L), normal
liver function (GOT and GPT within the normal range),
normal kidney function and normal serum creatinine
(<1.2 mg/dl) were mandatory to participate in this study.
The study was approved by the local Ethics Committee of
the Ruhr-University Bochum.
Blood Sampling and Intervention
All participants were assigned in a prospective, uncon-
trolled, open crossover design to three different treat-
ment schemes for initiating the antiplatelet treatment
with aspirin (ASPIRIN
®; Bayer Health Care; Leverkusen,
Germany): the first treatment option was aspirin 500 mg
given intravenously and contra-laterally to the blood
donor’s arm (regimen 1), secondly an aspirin 500 mg
tablet taken orally (regimen 2) and the third option was
an oral dose of 200 mg aspirin for the first two
subsequent days, followed by 100 mg aspirin daily for
5 days (regimen 3). The study medication was taken in
t h ep r e s e n c eo fas t u d yi n v e s t i g a t o r .T h el a b o r a t o r y
technician for aggregometry was blinded for the treat-
ment regimen and the aspirin dose used. The wash-out
period between each test series lasted more than two
weeks.
Blood samples were drawn with an 18 gauge needle
from an antecubital vein before and after intake of the
initial dose. The first 10 ml of blood were discarded to
avoid spontaneous platelet activation after insertion of
the needle. Blood was then collected in 4.0 ml blood
tubes containing 0.4 ml citrate (KABE Labortechnik,
Nümbrecht, Germany). For practical reasons, different
time intervals for blood drawing were set in order to
reduce the number of blood samples and were ceased
when a consistent antiaggregatory effect became appar-
ent (Table 1). Blood samples were taken for each treat-
ment option at baseline, after 5, 10, 15, 30, 45, 60, 120,
1 8 0 ,2 4 0a n d3 6 0m i n u t e s( m i n ) .B e c a u s eo ft h e
expected rapid-onset effect of 500 mg aspirin, either
intravenously (regimen 1) or orally applied (regimen 2),
additional measurements were performed after 0.5, 1,
2.5 and 7.5 min. For dosing regimen 3, all measure-
ments were repeated on day 2. To evaluate the time
period until the antiplatelet effect of aspirin was no
longer detectable, subjects of treatment schemes 2 and 3
were monitored once daily during the wash-out phase
after aspirin cessation.
Impedance Aggregometry
Platelet function testing wasd o n eb yu s i n gi m p e d a n c e
aggregometry (Model 590, Chrono-log Corporation,
Havertown, PA, USA) as previously described [8,9] and
the data were analyzed with the AggroLink software
package. This system measures the change of electrical
impedance in the test cuvette caused by aggregation and
adhesion of platelets to the electrode’s surface. Impe-
dance aggregometry testing with arachidonic acid and
collagen (Chrono-Par, Chrono-log Corporation, Haver-
town, PA, USA) was performed at the time intervals
described above. Measurements were carried out at
37°C and a stirring speed of 1000 rpm between 60 to
180 min after blood collection. 500 μlo fc i t r a t e db l o o d
was diluted 1:1 with sodium chloride 0.9% and heated
for at least 5 min at 37°C in a polycarbonate cuvette.
After calibration was performed and a stable baseline
(steady state) had been established, the two agonists
were added to different aliquots and aggregation was
monitored for 6 min. As agonists 10 μM arachidonic
acid (AA) with a final concentration of 0.5 mM and 2 μl
collagen with a final concentration of 2 μg/ml were used
and the maximum change of impedance (Ω)a sw e l la s
the area under the impedance curve (AUC) were
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Page 2 of 8recorded. Aspirin low response (insufficient platelet
inhibitory response) as the main outcome parameter
w a sd e f i n e da sac h a n g eo fi m p e d a n c ee x c e e d i n g0Ω
after stimulation with AA in accordance with previous
studies and recommendations [9,10]. Accordingly suffi-
cient platelet inhibitory resp o n s ea n de f f e c t i v ea s p i r i n
responsiveness stands for 0 Ω.
Statistics
Our study had a 3-period 3-treatment crossover design.
All impedance or AUC values for the three treatment
regimes were averaged for each measurement time
point. Variables are presented as mean ± standard devia-
tion (SD). Differences in means between the two oral
aspirin groups were tested for significance using the
paired Student’s t test under the Bonferroni-adjusted
significance level of p = 0.0045 (= 0.05/11) for multiple
comparisons. Data are presented as mean values (95%
confidence interval) for single treatment groups and
mean (99.55% confidence interval) when analyzing mul-
tiple comparisons of mean differences.
To calculate the mean and standard deviation of ohm
and AUC values without the intake of aspirin, 10 measure-
ments of impedance and AUC values at identical time
points of regimen 2 from basal (0 min) until 240 min were
taken and the coefficient of variation determined. All ana-
lyses were performed using SAS, version 9.2 (SAS Institute
Inc., Cary, NC, USA). All curves were plotted using SPSS,
version 18.0 (SPSS Inc., Chicago, Ill, USA).
Results
Baseline Characteristics
12 healthy volunteers (6 male, 6 female; mean age 34.8 ±
9.2 years) participated in this study. Measurements for
consistency without the intake of aspirin showed for AA
stimulated samples a mean value of 14.1 ± 1.4 Ω for
impedance and 64.82 ± 6.0 arbitrary units (AU) for AUC
analysis. For collagen stimulation the results were 21.0 ±
1.7 Ω and 80.43 ± 6.5 AU respectively. The results
revealed a good reproducibility with a standard deviation
of 1.4 Ω and a variation coefficient of 0.10.
There were no significant differences between the
three groups at baseline: for treatment regimen 1
(500 mg aspirin i.v.) the values were 15.3 ± 2.1 Ω for
stimulation with AA and 21.4 ± 3.5 Ω for collagen
induced aggregometry, compared to 13.6 ± 4.4 Ω and
20.1 ± 6.4 Ω for regimen 2 (aspirin 500 mg orally) and
for regimen 3 with 200 mg aspirin orally as starting
dose 13.2 ± 2.3 Ω and 16.9 ± 4.0 Ω.
On comparing the different time points, mean impe-
dance values after oral intake of either 200 mg or 500 mg
aspirin showed no significant differences, yet a wide
range of values with high inter- and intraindividual differ-
ences were present (Table 2). In contrast, intravenous
500 mg aspirin attained a sufficient platelet inhibitory
response of 0 Ω in all 12 volunteers within 30 seconds.
The results of stimulation using collagen, which is
unspecific for the evaluation of the antiplatelet effective-
ness of aspirin, revealed no consistent influence of either
aspirin treatment options and were therefore not
included in the further analysis (Table 3).
Time Course of the Antiplatelet Effect of Different Aspirin
Dosing Schemes
An overview of the mean time until the inhibitory anti-
platelet effect was evident according to the different
aspirin doses is provided in Figure 1. As can be seen in
Figures 2, 3, 4, the curves after oral and intravenous
administration differed significantly (p < 0.001 after
5 min, p = 0.04 after 10 min and p = 0.07 after 15 min
respectively). Initiating antiplatelet therapy with intrave-
nous 500 mg aspirin resulted in a consistent, sufficient
and immediate platelet inhibitory response (0 Ω)w i t h i n
30 seconds (Figure 2) in all 12 volunteers. When aspirin
treatment according to schemes 2 and 3 was initiated,
high inter- and intra-individual differences existed before
gaining effective aspirin responsiveness (Figure 3 and 4).
In both oral aspirin dosages, a clear decline of mean
impedance values was visible at 30 min, yet not reaching
sufficient antiplatelet response. The mean time until an
adequate antiplatelet response was demonstrated for the
treatment option of oral 500 mg aspirin was 74 min
(minimum 7.5 min, maximum 360 min). Of note, in this
group only 10 out of 12 volunteers had a sufficient inhi-
bition of AA-induced platelet aggregation within
60 minutes.
In the third aspirin starting scheme with two days of
aspirin 200 mg (followed by aspirin 100 mg daily) the
platelet inhibitory effect of aspirin was more variable. Alto-
gether, an adequate antiplatelet effect in all participants
Table 1 Overview of the measurement time points
Aspirin Dose (mg) Time in minutes
b 0.5 1 2.5 5 10 15 30 45 60 120 180 240 360
500 i.v. xxxxxxxxxx x x x -
500 oral x-xxx xxxxx x x x x
200 oral x---x xxxxx x x x x
b indicates basal measurement, i.v. intravenous.
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(mean time lag 662 min (11.2 hours); minimum 5 min,
maximum 3 days). Of note, 8 out of 12 volunteers had an
adequate inhibitory effect after 60 min. For this treatment
group (200 mg aspirin orally) three different types of time-
dependent antiplatelet effectiveness were observed: Per-
sons with fast reactions, medium fast and slow reactions
(Figure 5).
Cessation of Aspirin Treatment - How Long Does the
Antiplatelet Effect Last?
Nine volunteers were followed during the wash-out per-
iod after aspirin cessation by daily baseline controls.
After the one-time oral intake of 500 mg aspirin,
3 participants showed normal aggregation results the
next day, 3 on the second day and 3 volunteers on the
third day. After being given 200 mg aspirin on two sub-
sequent days followed by 100 mg daily for 5 days,
2 volunteers had normal values the day after aspirin
cessation, 2 after two days, 3 after 3 days and in 2 volun-
teers the aspirin effect lasted 4 days.
Discussion
Platelet aggregation profiles of our healthy participants
showed a variable time response to the three different
treatment dosages of aspirin in all volunteers but also
revealed a high inter- and intra-individual variability
among the participants. On an intravenous loading dose
Table 2 Mean impedance values (in ohm (Ω)) comparing 200 mg and 500 mg oral and 500 mg intravenous aspirin
dosages
Aspirin 200 mg oral Aspirin 500 mg oral Aspirin 500 mg i.v. P-value (200 mg vs. 500 mg oral)
Day 1 (0 min) 13.2 (11.7 - 14.6) 13.6 (10.8 - 16.4) 15.3 (14.0 - 16.7) 0.80
5 min 12.8 (9.9 - 15.6) 12.8 (10.2 - 15.4) 0.0 0.96
10 min 12.3 (9.4 - 15.1) 11.8 (7.6 - 16.1) 0.0 0.87
15 min 9.3 (5.4 - 13.3) 8.3 (4.4 - 12.1) 0.2 (-0.4 - +0.8) 0.68
30 min 3.8 (0.6 - 6.9) 4.2 (0.5 - 7.8) 0.0 0.87
45 min 3.8 (0.4 - 7.3) 2.6 (-0.05 - 5.2) 0.25 (-0.5 - +1.0) 0.52
60 min 3.9 (0.06 - 7.8) 1.3 (-0.3 - 2.9) 0.2 (-0.4 - +0.8) 0.17
120 min 3.2 (-0.6 - 6.9) 1.3 (-0.6 - 3.1) 0.2 (-0.4 - +0.8) 0.30
180 min 1.8 (-0.6 - 4.1) 1.3 (-0.6 - 3.3) 0.0 0.69
240 min 2.1 (-0.4 - 4.6) 0.7 (-0.8 - 2.1) 0.2 (-0.4 - +0.8) 0.11
Day 2 (0 min) 3.0 (0.6 - 5.4) 3.3 (-1.0 - 7.7) 0.6 (-0.5 - +1.6) 0.89
Data presented are mean and 95% confidence interval. Significance was tested by using the paired student’s t test under the Bonferroni-adjusted significance
level of p = 0.0045 (= 0.05/11) for multiple comparisons.
Table 3 Results of collagen-induced aggregometry for the 3 treatment groups
Aspirin 200 mg oral Aspirin 500 mg oral Aspirin 500 mg i.v. P-value (200 mg vs. 500 mg oral)
basal 16.9 (14.4-19.5) 20.1 (16.0-24.1) 21.4 (19.2-23.6) 0.19
0.5 min - - 15.9 (13.4-18.4) -
1 min - - 17.0 (14.7-19.3) -
2.5 min - - 16.7 (14.1-19.2) -
5 min 17.1 (14.5-19.7) 18.8 (15.3-22.2) 16.2 (13.4-19.0) 0.49
7.5 min - - 17.0 (12.8-21.2) -
10 min 15.8 (12.2-19.5) 19.6 (15.5-23.6) 18.8 (13.2-24.4) 0.19
15 min 15.2 (11.3-19.0) 19.8 (16.0-23.7) 16.6 (9.1-24.1) 0.14
30 min 14.6 (10.5-18.7) 13.7 (9.0-18.4) 17.8 (15.1-20.5) 0.77
45 min 12.6 (8.6-16.6) 12.3 (7.0-17.6) 12.8 (2.6-22.9) 0.79
60 min 11.8 (8.3-15.2) 13.0 (7.2-18.8) 16.8 (11.7-21.9) 0.74
120 min 14.7 (11.0-18.4) 16.2 (10.6-21.9) 17.4 (11.9-22.6) 0.68
180 min 14.0 (10.7-17.3) 15.7 (6.5-24.8) 16.8 (9.8-23.8) 0.69
240 min 14.4 (7.7-21.1) 13.3 (3.0-23.7) 18.6 (14.2-23.0) 0.82
Day 2 14.8 (11.4-18.1) 14.8 (8.5-21.1) 16.0 (13.1-18.9) 0.59
Values in ohm (Ω) with mean (95% CI); significance was tested by using the paired Student’s t test under the Bonferroni-adjusted significance level of p = 0.0045
(= 0.05/11) for multiple comparisons. vs - versus.
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Page 4 of 8of 500 mg aspirin, our study indicated an immediate
antiplatelet effect within 30 seconds, compared to a
median time of 74 min after oral intake of 500 mg and
of 11.2 hours when using 200 mg aspirin as a starting
dose, respectively. These data suggest using a higher
aspirin loading dose intravenously in order to achieve an
early and reliable platelet inhibitory effect in acute
stroke patients.
Commonly, ischemic events occurring despite aspirin
therapy are qualified as therapy failures and termed as
‘clinical aspirin resistance’ [11]. Yet atherothrombotic
complications can even occur during effective concomi-
tant aspirin therapy when other amplification pathways
play a role in platelet activation. Pathways stimulated by
adenosine diphosphate (ADP), collagen, thrombin, adre-
naline and sheer stress remain basically unaltered by
aspirin. Therefore ‘clinical aspirin resistance’ should be
differentiated from ‘laboratory aspirin resistance’,i n
which laboratory tests visualize the failure of aspirin to
inhibit thromboxane formation entailing an insufficient
inhibition of platelet function [11].
There is growing evidence that ‘laboratory aspirin resis-
tance’ is of high clinical value in stroke management.
Several studies measuring platelet aggregation in patients
with cerebrovascular diseases were able to demonstrate
different types of aspirin non-responders, a higher inci-
dence of aspirin non-response with lower aspirin doses
and enteric-coated aspirin preparations, higher recurrence
Figure 1 Comparing treatment options for initiating aspirin
treatment. Mean time until the inhibitory antiplatelet effect of
aspirin was evident following an aspirin dose of 500 mg
intravenously (i.v.) (within 0.5 min), 500 mg aspirin tablets orally
(74 ± 105 min) and when 200 mg aspirin was given on the first
2 days (662 minutes (11.2 hours) ± 1390 minutes).
Figure 2 Time course of treatment regimen 1 - 500 mg aspirin
i.v. Impedance values in ohm (Ω). Data presented are mean and
95% confidence interval.
Figure 3 Time course of treatment regimen 2 - 500 mg oral
aspirin. Impedance values in ohm (Ω). Data presented are mean
and 95% confidence interval.
Figure 4 Time course of treatment regimen 3 - 200 mg oral
aspirin dosage for 2 days followed by 100 mg/d. Impedance
values in ohm (Ω). Data presented are mean and 95% confidence
interval.
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dose-dependent time intervals for recurrent events
[12-16]. In this context platelet function testing allows
adjustment of the antiplatelet medication in case of hypo-
responsiveness and the monitoring of compliance to
antiplatelet therapy [16-18].
After oral ingestion, aspirin is rapidly absorbed in the
stomach and the upper intestine, reaching peak concen-
tration in the blood within 30 to 40 min and inhibiting
platelet function within one hour after intake [19]. The
oral bioavailability of aspirin is approximately 40 to 50%,
differing over a range of dosages as it is metabolized
r a p i d l yb ye s t e r a s e si nt h eg u ta n di nt h el i v e rb e f o r e
entering the systemic blood stream [20]. The intrave-
nous injection of aspirin avoids this rapid presystemic
metabolization and first-pass effect, leading to a bio-
availability of up to 100%, thus enabling a more immedi-
ate antiplatelet effectiveness [21,22].
Pharmacodynamic studies on different aspirin doses
for the treatment of acute stroke management are not
available. Our results revealed a rapid antiplatelet effect
within 30 seconds after intravenous injection of 500 mg
aspirin. Orally administere da s p i r i ni nd o s e so f5 0 0m g
and 200 mg led to a variable inter- and intraindividual
onset of action in our young healthy volunteers of up to
6 hours and 3 days respectively. Another study in nor-
mal volunteers showed that different oral preparations
of 81 mg aspirin required significantly more time to
reach maximum antithrombotic protection than pre-
parations of 325 mg aspirin (day 2 and 3 versus day 1)
[23]. In addition to aspirin dose and modes of adminis-
tration, factors such as co-medications, gastric motility
dysfunctions or gastric abnormalities in older patients or
physical or emotional stress could influence the onset of
the aspirin effect [24,25]. Intravenous administration of
a high aspirin dosage could bypass dose- and absorp-
tion-dependent factors. A delay of aspirin response
bears the disadvantage of a higher risk of recurrent cere-
bral ischemic events which is highest during the first
days after acute cerebrovascular ischemia occurred. The
estimated recurrence risk within the first 7 days after
the first manifestation of TIA or minor stroke is up to
12.8% [26,27]. The therapeutic concept of the EXPRESS
study contained an immediate initial therapy after diag-
nosis of TIA or stroke with 300 mg of aspirin followed
by a prescription of either aspirin 75 mg or clopidogrel
75 mg [28]. A loading dose of 300 mg clopidogrel was
recommended when clopidogrel was given. The results
of this study demonstrated that the immediate treatment
start after TIA was markedly effective in preventing
recurrent stroke (80% risk reduction) [28]. Both the
EXPRESS clinical findings and our laboratory data sup-
port the necessity to initiate antiplatelet treatment
earlier and more aggressively after acute strokes.
Aspirin, an irreversible non-selective cyclooxygenase
inhibitor, solely blocks one amplification pathway of pla-
telet activation with inhibition of the thromboxane A2
synthesis. Due to the irreversible binding, this effect
lasts 7 to 10 days throughout the entire life span of the
platelet. Keeping this aspect in mind as well as the
assumption that stopping aspirin intake will result in
normal platelet function 4 to 5 days later in approxi-
mately 50% of platelets and after 7 to 10 days in more
than 90%, it is recommended to stop administering
aspirin 7 to 10 days prior to surgery [29]. In accordance
with other working groups [23,30-32] our study demon-
strated that normal baseline values in aggregometry test-
ing were reached within 3 to 4 days after aspirin
cessation. Hence, aggregometry testing to monitor the
activity of antiplatelet agents could help to minimize
postponement of surgical or interventional procedures
in patients treated with antiplatelet agents.
All in all, new concepts for a more rapid and reliable
approach for starting antiplatelet therapy of acute stroke
should be sought. Aggregometry-guided control of differ-
ent therapeutic regimens could assist in this process.
Taking all this into consideration, we recommend carry-
ing out a sufficiently powered clinical trial, in which dif-
ferent loading doses should be compared in order to
investigate the optimal response to aspirin in acute stroke
patients without causing an exceedingly high bleeding
incidence.
Our study has several limitations. The size of our
study cohort was relatively small, but all volunteers par-
ticipated in all three dosing regimens to allow not only
inter- but also intraindividual analysis. Furthermore our
participants were healthy young persons without any
Figure 5 Interindividual variability of the antiplatelet response
when a loading dose of 200 mg aspirin was taken. Impedance
values in ohm (Ω). Data presented are mean and 95% confidence
interval.
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Page 6 of 8co-morbidities or co-medication. However, these results
of the platelet function tests on our healthy subjects
cannot automatically be transferred to acute stroke
patients. The pharmacokinetic and pharmacodynamic
process of aspirin metabolization in stroke patients
could be influenced by concomitant diseases and co-
medications leading to varied drug absorption due to
pathophysiological changes in the gastrointestinal tract
or drug-drug interactions [24]. Additionally, platelet
hyperreactivity and variations of fibrinolytic activity in
acute ischemic stroke are further aspects which could
alter aspirin responsiveness and the ensuing results of
platelet function testing [12,17]. And finally, we cannot
deduce on the basis of our results any consequences for
thromboembolic and bleeding rates in acute stroke
patients.
Conclusions
Our study reveals that the antiplatelet effect differs sig-
nificantly between the three different aspirin starting
dosages used with a high inter- and intraindividual
variability of antiplatelet response in our healthy volun-
teers. The results on our healthy volunteers suggest that
it could be preferable to initiate acute stroke therapy
with an intravenous loading dose of 500 mg aspirin in
order to ensure an early platelet inhibitory effect. How-
ever, clinical outcome studies must first define the best
way to initiate antiplatelet treatment with aspirin.
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